CONTEXT: Family interventions have been found to hasten episode recovery and delay recurrences among adults with bipolar disorder. OBJECTIVE: To examine the benefits of family-focused treatment for adolescents (FFT-A) andpharmacotherapy in the 2-year course of adolescent bipolar disorder. DESIGN: Two-site outpatient randomized controlled trial with 2-year follow-up. PATIENTS: A referred sample of 58 adolescents (mean [SD] age, 14.5 [1.6] years) with bipolar I (n = 38), II (n = 6), or not otherwise specified disorder (n = 14) with a mood episode in the prior 3 months. INTERVENTIONS: Patients were randomly assigned to FFT-A and protocol pharmacotherapy (n = 30) or enhanced care (EC) and protocol pharmacotherapy (n = 28). The FFT-A consisted of 21 sessions in 9 months of psychoeducation, communication training, and problem-solving skills training. The EC consisted of 3 family sessions focused on relapse prevention. MAIN OUTCOME MEASURES: Independent "blind" evaluators assessed patients every 3 to 6 months for 2 years. Outcomes included time to recovery from the index episode, time to recurrence, weeks in episode or remission, and mood symptom severity scores. RESULTS: Analyses were by intent to treat. Rates of 2-year study completion did not differ across the FFT-A (60.0%) and EC conditions (64.3%). Although there were no group differences in rates of recovery from the index episode, patients in FFT-A recovered from their baseline depressive symptoms faster than patients in EC (hazard ratio, 1.85; 95% confidence interval, 1.04-3.29; P = .04). The groups did not differ in time to recurrence of depression or mania, but patients in FFT-A spent fewer weeks in depressive episodes and had a more favorable trajectory of depression symptoms for 2 years. CONCLUSIONS: Family-focused therapy is effective in combination with pharmacotherapy in stabilizing bipolar depressive symptoms among adolescents. To establish full recovery, FFT-A may need to be supplemented with systematic care interventions effective for mania symptoms.
RCT Entities:
CONTEXT: Family interventions have been found to hasten episode recovery and delay recurrences among adults with bipolar disorder. OBJECTIVE: To examine the benefits of family-focused treatment for adolescents (FFT-A) and pharmacotherapy in the 2-year course of adolescent bipolar disorder. DESIGN: Two-site outpatient randomized controlled trial with 2-year follow-up. PATIENTS: A referred sample of 58 adolescents (mean [SD] age, 14.5 [1.6] years) with bipolar I (n = 38), II (n = 6), or not otherwise specified disorder (n = 14) with a mood episode in the prior 3 months. INTERVENTIONS:Patients were randomly assigned to FFT-A and protocol pharmacotherapy (n = 30) or enhanced care (EC) and protocol pharmacotherapy (n = 28). The FFT-A consisted of 21 sessions in 9 months of psychoeducation, communication training, and problem-solving skills training. The EC consisted of 3 family sessions focused on relapse prevention. MAIN OUTCOME MEASURES: Independent "blind" evaluators assessed patients every 3 to 6 months for 2 years. Outcomes included time to recovery from the index episode, time to recurrence, weeks in episode or remission, and mood symptom severity scores. RESULTS: Analyses were by intent to treat. Rates of 2-year study completion did not differ across the FFT-A (60.0%) and EC conditions (64.3%). Although there were no group differences in rates of recovery from the index episode, patients in FFT-A recovered from their baseline depressive symptoms faster than patients in EC (hazard ratio, 1.85; 95% confidence interval, 1.04-3.29; P = .04). The groups did not differ in time to recurrence of depression or mania, but patients in FFT-A spent fewer weeks in depressive episodes and had a more favorable trajectory of depression symptoms for 2 years. CONCLUSIONS: Family-focused therapy is effective in combination with pharmacotherapy in stabilizing bipolar depressive symptoms among adolescents. To establish full recovery, FFT-A may need to be supplemented with systematic care interventions effective for mania symptoms.
Authors: Roy H Perlis; Sachiko Miyahara; Lauren B Marangell; Stephen R Wisniewski; Michael Ostacher; Melissa P DelBello; Charles L Bowden; Gary S Sachs; Andrew A Nierenberg Journal: Biol Psychiatry Date: 2004-05-01 Impact factor: 13.382
Authors: William Coryell; David Solomon; Carolyn Turvey; Martin Keller; Andrew C Leon; Jean Endicott; Pamela Schettler; Lewis Judd; Timothy Mueller Journal: Arch Gen Psychiatry Date: 2003-09
Authors: Christopher D Schneck; David J Miklowitz; Joseph R Calabrese; Michael H Allen; Marshall R Thomas; Stephen R Wisniewski; Sachiko Miyahara; Melvin D Shelton; Terence A Ketter; Joseph F Goldberg; Charles L Bowden; Gary S Sachs Journal: Am J Psychiatry Date: 2004-10 Impact factor: 18.112
Authors: David J Miklowitz; Christopher D Schneck; Patricia D Walshaw; Amy S Garrett; Manpreet K Singh; Catherine A Sugar; Kiki D Chang Journal: Early Interv Psychiatry Date: 2017-08-04 Impact factor: 2.732
Authors: Heather A MacPherson; Amanda L Ruggieri; Rachel E Christensen; Elana Schettini; Kerri L Kim; Sarah A Thomas; Daniel P Dickstein Journal: J Affect Disord Date: 2018-04-16 Impact factor: 4.839
Authors: Manivel Rengasamy; Brandon M Mansoor; Robert Hilton; Giovanna Porta; Jiayan He; Graham J Emslie; Taryn Mayes; Gregory N Clarke; Karen Dineen Wagner; Martin B Keller; Neal D Ryan; Boris Birmaher; Wael Shamseddeen; Joan Rosenbaum Asarnow; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-04 Impact factor: 8.829
Authors: Soledad Romero; Boris Birmaher; David A Axelson; Ana-Maria Iosif; Douglas E Williamson; Mary Kay Gill; Benjamin I Goldstein; Michael A Strober; Jeffrey Hunt; Tina R Goldstein; Christianne Esposito-Smythers; Satish Iyengar; Neal D Ryan; Martin Keller Journal: J Clin Psychiatry Date: 2009-10 Impact factor: 4.384